BRAF and metastatic melanoma: The BRAF and v-raf murine sarcoma viral oncogene homolog B1 inhibitors, vemurafenib and dafrafenib, have been recently approved by the Food and Drug Administration (FDA) for treatment of metastatic melanoma harboring BRAFV600 mutation.